UBS Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $37

Benzinga Newsdesk www.benzinga.com Negative 73.6%

Neg 73.6% Neu 0% Pos 0%

UBS analyst David Dai maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and lowers the price target from $38 to $37.